Biagio Ricciuti: Mechanisms of acquired resistance to PD-(L)1 blockade in NSCLC

Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on LinkedIn:

“Now out in the Journal of Clinical Oncology our effort to elucidate mechanisms of acquired resistance to PD-(L)1 blockade in NSCLC. We identified acquired genomic and immunophenotypic changes that may contribute to the development of resistance to ICI +/- chemotherapy in patients with lung cancer.”